» Articles » PMID: 30418409

Bacteriophage Therapy Testing Against Shigella Flexneri in a Novel Human Intestinal Organoid-Derived Infection Model

Overview
Publisher Wiley
Date 2018 Nov 13
PMID 30418409
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Enteric bacterial pathogens cause diarrheal disease and mortality at significant rates throughout the world, particularly in children younger than 5 years. Our ability to combat bacterial pathogens has been hindered by antibiotic resistance, a lack of effective vaccines, and accurate models of infection. With the renewed interest in bacteriophage therapy, we sought to use a novel human intestinal model to investigate the efficacy of a newly isolated bacteriophage against Shigella flexneri.

Methods: An S. flexneri 2457T-specific bacteriophage was isolated and assessed through kill curve experiments and infection assays with colorectal adenocarcinoma HT-29 cells and a novel human intestinal organoid-derived epithelial monolayer model. In our treatment protocol, organoids were generated from intestinal crypt stem cells, expanded in culture, and seeded onto transwells to establish 2-dimensional monolayers that differentiate into intestinal cells.

Results: The isolated bacteriophage efficiently killed S. flexneri 2457T, other S. flexneri strains, and a strain of 2457T harboring an antibiotic resistance cassette. Analyses with laboratory and commensal Escherichia coli strains demonstrated that the bacteriophage was specific to S. flexneri, as observed under co-culture conditions. Importantly, the bacteriophage prevented both S. flexneri 2457T epithelial cell adherence and invasion in both infection models.

Conclusions: Bacteriophages offer feasible alternatives to antibiotics for eliminating enteric pathogens, confirmed here by the bacteriophage-targeted killing of S. flexneri. Furthermore, application of the organoid model has provided important insight into Shigella pathogenesis and bacteriophage-dependent intervention strategies. The screening platform described herein provides proof-of-concept analysis for the development of novel bacteriophage therapies to target antibiotic-resistant pathogens.

Citing Articles

Development of a therapeutic delivery platform with reduced colonization potential.

Alexander L, Khalid S, Gallego-Lopez G, Astmann T, Oh J, Heggen M Appl Environ Microbiol. 2024; 90(11):e0031224.

PMID: 39480094 PMC: 11577788. DOI: 10.1128/aem.00312-24.


Recent Advances in Graphene Oxide-Based on Organoid Culture as Disease Model and Cell Behavior - A Systematic Literature Review.

Sulaksono H, Annisa A, Ruslami R, Mufeeduzzaman M, Panatarani C, Hermawan W Int J Nanomedicine. 2024; 19:6201-6228.

PMID: 38911499 PMC: 11193994. DOI: 10.2147/IJN.S455940.


Advancements in understanding bacterial enteritis pathogenesis through organoids.

Wu Z, Liu H, Wang X Mol Biol Rep. 2024; 51(1):512.

PMID: 38622483 DOI: 10.1007/s11033-024-09495-5.


Bacteriophages and Their Host Range in Multidrug-Resistant Bacterial Disease Treatment.

Chung K, Liau X, Tang S Pharmaceuticals (Basel). 2023; 16(10).

PMID: 37895938 PMC: 10610060. DOI: 10.3390/ph16101467.


Functional assays to evaluate antibody-mediated responses against : a review.

Boero E, Vezzani G, Micoli F, Pizza M, Rossi O Front Cell Infect Microbiol. 2023; 13:1171213.

PMID: 37260708 PMC: 10227456. DOI: 10.3389/fcimb.2023.1171213.


References
1.
Citorik R, Mimee M, Lu T . Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases. Nat Biotechnol. 2014; 32(11):1141-5. PMC: 4237163. DOI: 10.1038/nbt.3011. View

2.
Prendergast A, Kelly P . Interactions between intestinal pathogens, enteropathy and malnutrition in developing countries. Curr Opin Infect Dis. 2016; 29(3):229-36. PMC: 4888918. DOI: 10.1097/QCO.0000000000000261. View

3.
Citorik R, Mimee M, Lu T . Bacteriophage-based synthetic biology for the study of infectious diseases. Curr Opin Microbiol. 2014; 19:59-69. PMC: 4125527. DOI: 10.1016/j.mib.2014.05.022. View

4.
Marks F, von Kalckreuth V, Aaby P, Adu-Sarkodie Y, El Tayeb M, Ali M . Incidence of invasive salmonella disease in sub-Saharan Africa: a multicentre population-based surveillance study. Lancet Glob Health. 2017; 5(3):e310-e323. PMC: 5316558. DOI: 10.1016/S2214-109X(17)30022-0. View

5.
Roberts M, Martin N, Kropinski A . The genome and proteome of coliphage T1. Virology. 2004; 318(1):245-66. DOI: 10.1016/j.virol.2003.09.020. View